AI Article Synopsis
- - Bacille Calmette-Guérin (BCG) is the primary vaccine for tuberculosis (TB), but its effectiveness varies by location, prompting research into ways to enhance its immune response.
- - The study investigates a genetically modified version of BCG, called rBCGΔureC∷hly, which expresses specific antigens associated with TB latency to improve the vaccine's efficacy.
- - Results show that this modified vaccine led to better long-term protection in mice against a specific strain of Mycobacterium tuberculosis, suggesting that incorporating these antigens can strengthen the immune response to TB.
Article Abstract
Bacille Calmette-Guérin (BCG) is the vaccine against tuberculosis (TB), but has varied efficacy in different geographical locations. Recombinant strategies to genetically modify the organism to enhance the quality of the immune response have aimed at improving BCG efficacy. Here we describe such a strategy using rBCGΔureC∷hly expressing defined latency-associated antigens and test this construct for long-term protection against an isolate of the Mycobacterium tuberculosis (Mtb) Beijing/W lineage. Expression of the antigens Rv2659c, Rv3407 and Rv1733c by rBCGΔureC∷hly improved long-term efficacy in both lung and spleen at day 200 post-infection after intradermal vaccination of mice. Our data support expression of Mtb latency associated antigens by rBCG to improve protection against Mtb.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.vaccine.2011.07.144 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!